Program
dapiglutide
Also written as “ZP7570”, “Dapiglutide 7.5 mg” and “Dual GLP-1/GLP-2 Receptor agonists”.
Its studies are mostly in Obesity, led by Zealand Pharma.
Furthest: phase 1, since Aug 8, 20234 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zealand Pharma | 40 open or running | phase 1since Aug 8, 2023 | May 15, 2019 | none ahead |
Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2019First study: early phase 1 study in HealthyFirst studyNCT03994549 · 64 enrolled · Germany
- Oct 20, 2020Early phase 1 study in HealthyNCT04612517 · 40 enrolled · Germany
- Aug 8, 2023Phase 1 study in OverweightNCT06000891 · 84 enrolled · Germany
- Dec 9, 2024Phase 1 study in OverweightNCT06758583 · 30 enrolled · Germany
TargetBeta
GLP1R →read by rule
“Dapiglutide is a dual Glucagon-like peptide-1-/Glucagon-like peptide-2 Receptor Agonist (GLP-1R/GLP-2RA) in clinical development for weight management.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06758583Overweight · Germany | 1 | Completed | Apr 12, 2025 | 30 |
| NCT06000891Overweight · Germany | 1 | Terminated | Feb 11, 2025 | 84 |
| NCT04612517Healthy · Germany | Early 1 | Completed | Aug 30, 2021 | 40 |
| NCT03994549Healthy · Germany | Early 1 | Completed | Nov 2, 2020 | 64 |
How it is read
Names in the registry
- “ZP7570”, 2 entries
- “Dapiglutide 7.5 mg”, 1 entry
- “Dual GLP-1/GLP-2 Receptor agonists”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.